

Jure Murgic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1510179/publications.pdf>

Version: 2024-02-01

64
papers

727
citations

687363

13
h-index

580821

25
g-index

64
all docs

64
docs citations

64
times ranked

1437
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of prior local therapy and outcomes with programmedâ€œdeath ligandâ€œ1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3
2	Radiation Therapy for Cure or Palliation: Case of the Immunosuppressed Patient With Multiple Primary Cancers and Liver Transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 581-582.	0.8	5
3	Alpha Satellite RNA Levels Are Upregulated in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Genes</i> , 2022, 13, 383.	2.4	9
4	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
5	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	1.9	10
6	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
7	Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 444-444.	1.6	0
8	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16526-e16526.	1.6	0
9	New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer. <i>Acta Medica Academica</i> , 2021, 50, 143.	0.8	5
10	PP-0162 MR-assisted whole salvage HDR prostate brachytherapy with intra-prostatic boost: a prospective study. <i>Radiotherapy and Oncology</i> , 2021, 158, S124-S125.	0.6	0
11	Genetics of Prostate Carcinoma. <i>Acta Medica Academica</i> , 2021, 50, 71.	0.8	3
12	Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience. <i>Radiation Oncology</i> , 2021, 16, 88.	2.7	3
13	In Regard to van Son etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 617-618.	0.8	1
14	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
15	Impact of performance status on treatment outcomes: A realâ€œworld study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
16	In Regard to Lee etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1392-1394.	0.8	1
17	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2020, , .	5.4	13
18	Oncologist Burnout Syndrome in Eastern Europe: Results of the Multinational Survey. <i>JCO Oncology Practice</i> , 2020, 16, e366-e376.	2.9	10

#	ARTICLE	IF	CITATIONS
19	Association of Triiodothyronine Levels With Prostate Cancer Histopathological Differentiation and Tumor Stage. <i>Anticancer Research</i> , 2020, 40, 2323-2329.	1.1	4
20	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
21	Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapy. <i>Brachytherapy</i> , 2019, 18, 567-573.	0.5	5
22	39 Determination of the Impact of Intratumoural Heterogeneity on Prognostic Biomarkers in Localized Prostate Cancer. <i>Radiotherapy and Oncology</i> , 2019, 139, S19-S20.	0.6	0
23	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 84-91.	0.8	36
24	The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 46-46.	1.6	1
25	Clinical recommendations for diagnosis, treatment and monitoring of patients with bladder cancer. <i>Lijecnicki Vjesnik</i> , 2019, 141, .	0.0	1
26	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 702-709.	0.8	1
27	Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2018, 17, 306-312.	0.5	3
28	A Biopsy Based Genomic Classifier Predicts Biochemical Failure and Metastasis after Definitive Radiation without Hormone Therapy in a Prospective Cohort of Intermediate-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S99.	0.8	0
29	Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 561-567.	0.8	54
30	A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 68-68.	1.6	0
31	Radiotherapy in the Management of Prostate Cancer. <i>Medical Radiology</i> , 2017, , 87-112.	0.1	0
32	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. <i>ESMO Open</i> , 2017, 2, e000123.	4.5	5
33	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 459-465.	0.6	18
34	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
35	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	1.9	37
36	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 42-42.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Comparison of conventionally fractionated and hypofractionated schedule for post-prostatectomy salvage radiotherapy: Early results from non-randomized observational study.. Journal of Clinical Oncology, 2017, 35, e551-e551.	1.6	0
38	MP14-04 OUTCOMES OF RADIATION FOLLOWING EXPECTANT MANAGEMENT FOR LOW RISK, LOCALIZED PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
39	225: Assessment of Biochemical Outcome with Increasing Dose Escalation in Localized Prostate Cancer (PCA) With Precision Image-Guided Radiotherapy (IGRT). Radiotherapy and Oncology, 2016, 120, S82.	0.6	0
40	Assessment of Biochemical Outcomes with Increasing Dose Escalation in Localized Prostate Cancer (PCa) Treated with Precision Image Guided Radiation Therapy (IGRT). International Journal of Radiation Oncology Biology Physics, 2016, 96, E228-E229.	0.8	0
41	Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP). ESMO Open, 2016, 1, e000049.	4.5	2
42	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2016, 15, 147-155.	0.5	28
43	Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy.. Journal of Clinical Oncology, 2016, 34, 101-101.	1.6	0
44	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5051-5051.	1.6	0
45	Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture. , 2016, , .		0
46	An Analysis of Inter-Observer Variability in Catheter Reconstruction and Dosimetric Implications in Ultrasound-Based High-Dose-Rate Brachytherapy for Prostate Cancer. Brachytherapy, 2015, 14, S96.	0.5	0
47	Time to Nadir PSA. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 465-471.	1.3	13
48	Sunitinib-induced thyrotoxicosis - a not so rare entity. Anticancer Research, 2015, 35, 481-5.	1.1	8
49	Tumor-Absorbed Dose Predicts Progression-Free Survival Following ¹³¹ I-Tositumomab Radioimmunotherapy. Journal of Nuclear Medicine, 2014, 55, 1047-1053.	5.0	51
50	Anatomic Variability of the Neurovascular Elements Defined by MRI. Brachytherapy, 2014, 13, S42-S43.	0.5	8
51	Familial Adenomatous Polyposis in Three Generations of a Single Family: A Case Study. Case Reports in Oncology, 2014, 7, 349-356.	0.7	1
52	Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy. Anticancer Research, 2014, 34, 3177-84.	1.1	27
53	High-dose-rate brachytherapy and concurrent chemoradiotherapy followed by surgery for stage Ib-Ib cervical cancer: single institution experience. Anticancer Research, 2014, 34, 3861-6.	1.1	5
54	Variation in External Sphincter Extension within and beyond the Prostate: Implications from MRI-Based Post Implant Segmental Dosimetry. Brachytherapy, 2013, 12, S33.	0.5	2

#	ARTICLE	IF	CITATIONS
55	Breast and gynecological cancers in Croatia, 1988-2008. <i>Croatian Medical Journal</i> , 2012, 53, 100-108.	0.7	7
56	The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer. <i>Radiation Oncology</i> , 2012, 7, 127.	2.7	8
57	Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer. <i>Collegium Antropologicum</i> , 2012, 36, 325-9.	0.2	5
58	Quality of life of Croatian breast cancer patients receiving adjuvant treatment--comparison to long-term breast cancer survivors. <i>Collegium Antropologicum</i> , 2012, 36, 1335-41.	0.2	8
59	Postoperative use of radioiodine (¹³¹ I): review of recommendations and guidelines. <i>Collegium Antropologicum</i> , 2011, 35, 587-94.	0.2	3
60	Radiation therapy in treatment of fibrodysplasia ossificans progressiva: a case report and review of the literature. <i>Collegium Antropologicum</i> , 2011, 35, 611-4.	0.2	7
61	Splenic irradiation in hematologic malignancies and other hematologic disorders--single institution experience. <i>Acta Clinica Croatica</i> , 2011, 50, 29-35.	0.2	5
62	Paget's disease in contralateral breast occurring 11 years after mastectomy for invasive ductal carcinoma. <i>Collegium Antropologicum</i> , 2009, 33, 327-9.	0.2	2
63	The ageing of Croatian population. <i>Collegium Antropologicum</i> , 2009, 33, 701-5.	0.2	3
64	Clinical guidelines development and usage: a critical insight and literature review: thyroid disease diagnostic algorithms. <i>Collegium Antropologicum</i> , 2008, 32, 1283-90.	0.2	1